首页> 外文期刊>European review for medical and pharmacological sciences. >A study on regulatory mechanism of miR-223 in ulcerative colitis through PI3K/Akt-mTOR signaling pathway
【24h】

A study on regulatory mechanism of miR-223 in ulcerative colitis through PI3K/Akt-mTOR signaling pathway

机译:PI3K / Akt-mTOR信号通路调控miR-223在溃疡性结肠炎中的调控机制

获取原文
       

摘要

OBJECTIVE: The aim of this study was to explore the regulatory mechanism of micro ribonucleic acid (miR)-223 in ulcerative colitis (UC) through the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)-mammalian target of rapamycin (mTOR) signaling pathway. MATERIALS AND METHODS: A total of 36 Sprague-Dawley (SD) rats were randomly divided into three groups, including normal group (n=12), model group (n=12) and inhibitor group (n=12). Rats in the normal group received no treatment. Rats in the model group were used to establish a UC model. Meanwhile, rats in the inhibitor group underwent intraperitoneal injection of inhibitor and establishment of the UC model. Subsequently, specimens were obtained for detection. Immunohistochemistry was applied to measure the expression of mTOR. Western blotting was adopted to determine the relative protein expressions of P85, P110 and phosphorylated Akt (p-Akt). Quantitative polymerase chain reaction (qPCR) was used to detect the mRNA expression of miR-223. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) was utilized to determine cell apoptosis. Furthermore, an enzyme-linked immunosorbent assay (ELISA) was conducted to measure the content of interleukin-1 beta (IL-1β) and IL-6. RESULTS: Immunohistochemistry showed that the positive expression of mTOR increased remarkably in the model group and inhibitor group when compared with that of the normal group (p0.05). However, it decreased notably in the inhibitor group when compared with the model group (p0.05). Western blotting indicated that the protein expressions of P85, P110 and p-Akt in model group and inhibitor group were significantly higher than the ones of the normal group (p0.05). However, the inhibitor group showed markedly lower relative protein expressions of P85, P110 and p-Akt than the ones of the model group (p0.05). Compared with the normal group, the expression level of miR-223 was significantly elevated in model group and inhibitor group (p0.05). However, there was no significant difference in the mRNA expression of miR-233 between the model group and the inhibitor group (p0.05). The apoptosis rate of the cells increased prominently in the model group and in the inhibitor group when compared with the normal group (p0.05). However, it was remarkably reduced in the inhibitor group than the model group (p0.05). In comparison with the normal group, the content of IL-1β and IL-6 was significantly up-regulated in the model group and in the inhibitor group (p0.05). However, it declined notably in the inhibitor group compared with the model group (p0.05). CONCLUSIONS: MiR-223 can trigger cell apoptosis and inflammation in UC by up-regulating the PI3K/Akt-mTOR signaling pathway.
机译:目的:本研究旨在探讨微核糖核酸(miR)-223通过磷脂酰肌醇3激酶(PI3K)/蛋白激酶B(Akt)-哺乳动物雷帕霉素靶点(UC)对溃疡性结肠炎(UC)的调节机制。 mTOR)信号通路。材料与方法:将36只SD大鼠随机分为三组,分别为正常组(n = 12),模型组(n = 12)和抑制剂组(n = 12)。正常组的大鼠不接受治疗。模型组采用大鼠建立UC模型。同时,抑制剂组的大鼠腹膜内注射抑制剂并建立UC模型。随后,获得样本进行检测。免疫组织化学法检测mTOR的表达。采用蛋白质印迹法测定P85,P110和磷酸化Akt(p-Akt)的相对蛋白表达。定量聚合酶链反应(qPCR)用于检测miR-223的mRNA表达。末端脱氧核苷酸转移酶介导的dUTP缺口末端标记(TUNEL)用于确定细胞凋亡。另外,进行了酶联免疫吸附测定(ELISA)以测量白介素-1β(IL-1β)和IL-6的含量。结果:免疫组化结果显示,模型组和抑制剂组mTOR的阳性表达明显高于正常组(p <0.05)。但是,与模型组相比,抑制剂组的显着下降(p <0.05)。 Western blotting结果显示,模型组和抑制剂组的P85,P110和p-Akt蛋白表达明显高于正常组(p <0.05)。然而,抑制剂组显示P85,P110和p-Akt的相对蛋白表达明显低于模型组(p <0.05)。与正常组比较,模型组和抑制剂组miR-223的表达水平明显升高(p <0.05)。然而,模型组和抑制剂组之间miR-233的mRNA表达没有显着差异(p> 0.05)。与正常组相比,模型组和抑制剂组的细胞凋亡率均显着增加(p <0.05)。但是,与模型组相比,抑制剂组中其显着降低(p <0.05)。与正常组相比,模型组和抑制剂组中IL-1β和IL-6的含量均显着上调(p <0.05)。然而,与模型组相比,抑制剂组的显着下降(p <0.05)。结论:MiR-223可通过上调PI3K / Akt-mTOR信号通路来触发UC细胞凋亡和炎症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号